SinoVeda Canada has revealed positive results following its comparative trial EffectiCal to Caltrate. The trial lasted 24 weeks and was a double blind, randomised trial with 97 post-menopausal women.
The results found that EffectiCal was equally as effective as Caltrate in measurements of bone formation and bone resorption. EffectiCal contains 300mg of calcium that is half the amount that is in Caltrate; Caltrate also has D3 as well.
It has also been revealed that those who took EffectiCal had fewer gastrointestinal side effects compared to those who took Caltrate.
Dr. Richard Fedorak, Principal Investigator and Professor of Medicine at the University of Alberta said: "EffectiCal is a compelling supplementation option for individuals concerned about bone loss and osteoporosis. Compared to Caltrate, EffectiCal is a very dose-efficient product and has a very benign side effect profile."
Each of the 97 women received each drug every day for 24 weeks; each subject received EffectiCal in one arm and Caltrate in the other. The average age of the subjects were 60 and there was no demographic differences or health risks between the groups at baseline.
Dr. Yun Tam, president, chief scientific officer, and co-founder of SinoVeda Canada. said: "We are extremely pleased with the clinical validation of EffectiCal's benefits. While we had long predicted these benefits based on our scientific know-how and rigorous laboratory testing, it is nice to see our predictions translated so cleanly into the clinic."